Her2-negative metastatic breast cancer
Showing 1 - 25 of >10,000
Breast Cancer Trial in Xi'an (metronomic oral vinorelbine plus anlotinib)
Recruiting
- Breast Cancer
- metronomic oral vinorelbine plus anlotinib
-
Xi'an, Shaanxi, ChinaXi'an International Medical Center Hospital
Aug 27, 2023
Breast Cancer Trial in Chengdu (Dalpiciclib combined with Letrozole)
Not yet recruiting
- Breast Cancer
- Dalpiciclib combined with Letrozole
-
Chengdu, Sichuan, ChinaWest China Hospital, Sichuan University
Aug 3, 2023
Metastatic Breast Cancer Trial in Seoul (Fulvestrant plus AI plus ribociclib, AI plus ribociclib)
Not yet recruiting
- Metastatic Breast Cancer
- Fulvestrant plus AI plus ribociclib
- AI plus ribociclib
-
Seoul, Korea, Republic ofKorea university Guro hospital
Apr 16, 2023
HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer, HER2-negative Circulating Tumor Cells, Postmenopausal
Active, not recruiting
- HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer
- +2 more
-
Ulm, Baden-Württemberg, GermanyUniversity Hospital Ulm -Department of Gynecology
Jul 27, 2022
Breast Cancer Trial (Capecitabine and Neratinib.)
Not yet recruiting
- Breast Cancer
- Capecitabine and Neratinib.
- (no location specified)
Jul 8, 2022
Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic
Active, not recruiting
- Breast Cancer
-
New York, New YorkNYU Perlmutter Cancer Center
Aug 5, 2022
Metastatic Breast Cancer (MBC) Trial in Nanjing, Shanghai (Paclitaxel Polymeric Micelles for Injection, Eribulin Mesilate
Recruiting
- Metastatic Breast Cancer (MBC)
- Paclitaxel Polymeric Micelles for Injection
- +5 more
-
Nanjing, Jiangsu, China
- +2 more
Nov 21, 2023
Real-World Data on First-line Treatment of Hormone
Recruiting
- Breast Cancer
-
Porto Alegre, Rio Grande Do Sul, BrazilCPO
Aug 15, 2022
Metastatic Breast Cancer Trial in Kansas City, Rochester, Saint Louis (ATI-2231, Capecitabine, Denosumab)
Not yet recruiting
- Metastatic Breast Cancer
- ATI-2231
- +3 more
-
Kansas City, Kansas
- +2 more
Mar 16, 2023
Breast Cancer Trial in Guangzhou (Capecitabine, Aromatase Inhibitor)
Active, not recruiting
- Breast Cancer
- Capecitabine
- Aromatase Inhibitor
-
Guangzhou, Guangdong, ChinaState Key Laboratory of Oncology in South China, Sun Yat-sen Uni
Jan 27, 2023
Breast Cancer, Metastatic Cancer Trial (SHR-1316, SHR6390, Nab paclitaxel)
Not yet recruiting
- Breast Cancer
- Metastatic Cancer
- SHR-1316
- +4 more
- (no location specified)
Jan 11, 2022
Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Adenocarcinoma, Metastatic Breast Carcinoma Trial in
Withdrawn
- Anatomic Stage IV Breast Cancer AJCC v8
- +4 more
- Bintrafusp Alfa
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Sep 2, 2022
Among Talazoparib-Treated HER2-Negative mBC With gBRCA1/2m
Completed
- Metastatic Breast Cancer
- Breast Neoplasms
-
New York, New YorkPfizer Inc.
Aug 5, 2022
ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Cancer Trial in Madison, Milwaukee (Onapristone, Fulvestrant)
Recruiting
- ER-positive Breast Cancer
- +2 more
-
Madison, Wisconsin
- +1 more
Jul 7, 2022
HER2-low in Metastatic Breast Cancer Patients
Not yet recruiting
- HER2-negative
- (no location specified)
Nov 9, 2023
ER-Positive Breast Cancer, HER2-negative Breast Cancer Trial in Houston (Fulvestrant Run-In, No Fulvestrant Run-In)
Recruiting
- ER-Positive Breast Cancer
- HER2-negative Breast Cancer
- Fulvestrant Run-In
- No Fulvestrant Run-In
-
Houston, TexasHouston Methodist Cancer Center
Mar 23, 2022
Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv Trial in Chicago
Not yet recruiting
- Estrogen-receptor-positive Breast Cancer
- +3 more
- elacestrant, palbociclib, abemaciclib, ribociclib
-
Chicago, IllinoisNorthwestern University
Sep 25, 2023
HER2-low in Unresectable and/or Metastatic Breast Cancer
Not yet recruiting
- Breast Neoplasms, Breast Cancer, Breast Carcinoma, Genes, HER-2, Genes, HER2
- (no location specified)
Nov 6, 2023
Breast Cancer Trial (Disitamab Vedotin+Anlotinib)
Not yet recruiting
- Breast Cancer
- Disitamab Vedotin+Anlotinib
- (no location specified)
Aug 14, 2023
Triple-Negative Breast Cancer Trial in Shanghai (Trastuzumab Deruxtecan)
Not yet recruiting
- Triple-Negative Breast Cancer
- Trastuzumab Deruxtecan
-
Shanghai, Shanghai, ChinaBreast cancer institute of Fudan University Cancer Hospital
Jul 12, 2023
Breast Cancer Metastatic Trial in Ravensburg (Ribociclib, Anastrozole, Letrozole)
Active, not recruiting
- Breast Cancer Metastatic
- Ribociclib
- +4 more
-
Ravensburg, GermanyStudienzentrum Onkologie Ravensburg
Mar 7, 2022
HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer Trial in Chicago, Minneapolis (ALX148, Fam-Trastuzumab
Recruiting
- HER2-positive Breast Cancer
- +17 more
- ALX148
- Fam-Trastuzumab Deruxtecan-Nxki
-
Chicago, Illinois
- +1 more
May 19, 2023
Breast Cancer Trial (Trastuzumab Deruxtecan)
Not yet recruiting
- Breast Cancer
- Trastuzumab Deruxtecan
- (no location specified)
Jul 10, 2023